Aspirin resistance is associated with a high incidence of myonecrosis after non-urgent percutaneous coronary intervention despite clopidogrel pretreatment  by Chen, Wai-Hong et al.
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OBJECTIVES We sought to investigate the effect of aspirin resistance on the incidence of myonecrosis after
non-urgent percutaneous coronary intervention (PCI) among patients pretreated with clopidogrel.
BACKGROUND Oral antiplatelet therapy using aspirin and a thienopyridine is the standard of care for
preventing thrombotic complications of PCI. The effect of aspirin resistance on the outcomes
of patients undergoing PCI is unknown.
METHODS We used the Ultegra Rapid Platelet Function Assay-ASA (Accumetrics Inc., San Diego,
California) to determine aspirin responsiveness of 151 patients scheduled for non-urgent
PCI. All patients received a 300-mg loading dose of clopidogrel 12 h before and a 75-mg
maintenance dose in the morning of the PCI. The incidence of myonecrosis was measured by
creatine kinase-myocardial band (CK-MB) and by troponin I (TnI) elevations after PCI.
RESULTS A total of 29 (19.2%) patients were noted to be aspirin-resistant. There was a significantly
higher incidence of female subjects in the aspirin-resistant versus aspirin-sensitive groups.
The incidence of any CK-MB elevation was 51.7% in aspirin-resistant patients and 24.6% in
aspirin-sensitive patients (p  0.006). Elevation of TnI was observed in 65.5% of
aspirin-resistant patients and 38.5% of aspirin-sensitive patients (p  0.012). Multivariate
analysis revealed aspirin resistance (odds ratio [OR] 2.9; 95% confidence interval [CI] 1.2 to
6.9; p  0.015) and bifurcation lesion (OR 2.8; 95% CI 1.3 to 6.0; p  0.007) to be
independent predictors of CK-MB elevation after PCI.
CONCLUSIONS Despite adequate pretreatment with clopidogrel, patients with aspirin resistance as measured
by a point-of-care assay have an increased risk of myonecrosis following non-urgent
PCI. (J Am Coll Cardiol 2004;43:1122–6) © 2004 by the American College of Cardiology
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Uarly complications of percutaneous coronary intervention
PCI) are caused by arterial thrombosis at the site of vessel
njury (1). More complete platelet inhibition using aspirin
nd a thienopyridine during PCI offers protection against
schemic complications (2–7). However, 8% to 45% (8–11)
f patients do not respond to aspirin therapy as determined
See page 1127
y different laboratory tests, and these aspirin-resistant
atients are at increased risk of thrombotic events (8,12–14).
he contribution of aspirin, a relatively weak antiplatelet
gent, to the prevention of thrombotic complications of PCI
n the presence of the full effect of a thienopyridine is
nknown. This study was designed to compare the inci-
ence of myonecrosis after PCI between aspirin-resistant
nd aspirin-sensitive patients pretreated with clopidogrel
12 h before PCI.
ETHODS
tudy population. Consecutive patients with aspirin use of
0- to 325-mg daily for 1 week and who were scheduled
From the Department of Medicine, The University of Hong Kong, Queen Mary
ospital, Hong Kong, China.
Manuscript received October 12, 2003; revised manuscript received November 30,A003, accepted December 9, 2003.or PCI were enrolled. Exclusion criteria included saphe-
ous vein graft intervention, chronic total occlusions that
ould not be crossed by guidewires, preprocedural elevation
f creatine kinase-myocardial band (CK-MB) or troponin I
TnI), planned use of glycoprotein IIb/IIIa inhibitors, and
he use of antiplatelet drugs other than aspirin or non-
teroidal anti-inflammatory drugs (NSAIDs) within two
eeks of the PCI. The local ethics committee on human
esearch approved the protocol, and all patients provided
ritten informed consent.
tudy protocol. After collecting baseline blood samples for
K-MB, TnI, and aspirin responsiveness, all patients re-
eived an oral loading dose of 300-mg clopidogrel 12 to 24 h
efore the procedure. The PCI procedure was performed on
he following day according to standard practice, after the
atients received an additional 75-mg maintenance dose of
lopidogrel. Unfractionated heparin 70 U/kg or enoxaparin
mg/kg was used for procedural anticoagulation at operator
iscretion. Following the procedure, blood samples for TnI
ere collected at 12 to 24 h, whereas those for CK-MB
ere collected at 6 to 8 h. If CK-MB was elevated, serial
easurements every 8 h were obtained and the peak level
as recorded. The CK-MB was considered elevated if 16
/l, which was further subdivided into 1 to 3  (16 to 48
/l), 3 to 5  (49 to 80 U/l), and 5  (80 U/l) normal.TnI value of 2.0 ng/ml was considered elevated.
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March 17, 2004:1122–6 Aspirin Resistance and Myonecrosis After PCIspirin-induced platelet inhibition was measured using a
ommercially available point-of-care assay, the Ultegra
apid Platelet Function Assay-ASA (RPFA-ASA) (Accu-
etrics Inc., San Diego, California). Citrate-anticoagulated
lood 2 ml was added to RPFA-ASA cartridges, which
ontain fibrinogen-coated beads and platelet agonists. If
spirin has produced the expected antiplatelet effect,
brinogen-coated beads will not agglutinate, and light
ransmission will not increase. The result is expressed as
spirin reaction unit (ARU). An ARU 550 indicates the
bsence of aspirin-induced platelet dysfunction, based on
orrelation with epinephrine-induced light transmission
ggregometry in aspirin-naive patient tested prior to and
etween 2 to 30 h after aspirin (325 mg) ingestion (15), and
s defined as aspirin-resistant. From this study, both the
Table 1. Baseline Clinical Characteristics
Age, yrs
Women, %
Weight, kg
Body mass index, kg/m2
Diabetes, %
Insulin-requiring
Oral drugs
Diet
Hypertension, %
Hyperlipidemia, %
Current smoker, %
Prior myocardial infarction, %
Total cholesterol, mmol/l
Creatinine, mol/l
Renal insufficiency, %
Baseline medications
Aspirin, mg
Aspirin 80 mg, %
Aspirin 100–160 mg, %
Aspirin 300 mg, %
Statin, %
Beta-blocker, %
ACE inhibitor, %
Calcium channel blocker, %
NSAID use 3 months to 2 weeks prior to PCI, %
Clopidogrel loading-to-device activation interval, h
Indication for PCI, %
Stable angina
Unstable angina 2 weeks
Myocardial infarction 2 weeks
Body mass index is calculated as the weight in kilograms div
ACE  angiotensin-converting enzyme; NSAID  non
Abbreviations and Acronyms
ARU  aspirin reaction unit
CK-MB  creatine kinase-myocardial band
NSAID  non-steroidal anti-inflammatory drugs
OR  odds ratio
PCI  percutaneous coronary intervention
TnI  troponin Iintervention.ensitivity (92%) and the specificity (85%) of this assay were
etermined. The coefficient of variance was 2.5% on re-
eated measures within patients. The between-patient co-
fficient of variance was 12.5% for baseline samples and
5.0% for post-aspirin samples. Digital angiograms were
nalyzed off-line using a computer-based edge-detection
rogram (CMS-GFT, MEDIS, Leiden, The Netherlands)
y experienced cardiologists who were unaware of the
atient characteristics and outcomes.
tatistical analysis. Comparisons between the two groups
ere performed by the Mann-Whitney U test for continu-
us variables and by the Fisher exact test for dichotomous
ariables. A logistic regression analysis using forward tech-
ique was employed to determine significant independent
redictors of CK-MB elevation. A significant level was
efined when p  0.05. All analyses were performed using
PSS 10.0 (SPSS Inc., Chicago, Illinois).
ESULTS
he clinical, angiographic, and procedural characteristics of
he patients are listed in Tables 1 and 2. A total of 29
19.2%) out of 151 enrolled patients were found to be
spirin-resistant. The characteristics were matched in the
Aspirin-Sensitive
(n  122)
Aspirin-Resistant
(n  29) p Value
63.7  11.8 65.6  9.7 0.426
19.7 44.8 0.007
67.2  11.2 66.9  12.9 0.901
25.4  3.1 26.6  3.9 0.099
40.2 44.8 0.678
3.3 10.3
32.0 31.0 0.130
4.9 3.4
77.0 75.9 1.000
77.9 72.4 0.625
12.3 17.2 0.542
35.2 27.6 0.516
4.52  1.28 4.08  0.82 0.112
113  67 123  46 0.156
11.5 24.1 0.130
117  49 103  20 0.401
18.9 17.2
76.2 82.8 0.322
4.9 0
82.8 79.3 0.788
74.6 82.8 0.469
55.7 48.3 0.536
27.0 37.9 0.262
1.6 3.4 0.475
24.6  6.9 25.8  12.2 0.697
0.492
72.1 79.3
10.7 3.4
17.2 17.2
y the square of height in meters.
dal anti-inflammatory drugs; PCI  percutaneous coronary
]
]ided b
-steroi
t
p
g
d
I
T
i
T
s
o
m
r
i
i

a
p
C
g
n
A  r
F
a
1124 Chen et al. JACC Vol. 43, No. 6, 2004
Aspirin Resistance and Myonecrosis After PCI March 17, 2004:1122–6wo groups except for the higher incidence of female
atients (44.8% vs 19.7%; p 0.007) in the aspirin-resistant
roup. All patients underwent successful PCI with 50%
iameter stenosis at the target lesion(s) and Thrombolysis
n Myocardial Infarction flow grade 3 after the intervention.
here was no bailout use of glycoprotein IIb/IIIa inhibitors
n any of the patients; no clinical bleeding events occurred.
he ratios of hemoglobin pre- and post-PCI in the aspirin-
ensitive and -resistant groups were identical at 0.96. None
f the patients developed contrast nephropathy. Post-PCI
Table 2. Angiographic and Procedural Charact
Lesion location, %
LAD
LCX
RCA
LM
Reference vessel diameter, mm
Restenotic lesions, %
Thrombus present, %
Bifurcation lesion, %
AHA/ACC classification, %
A/B1
B2/C
Procedural anticoagulation
Unfractionated heparin, %
Activated clotting time, s
No. of lesions treated
Stents placed, %
No. of stents per procedure
Maximal stent inflation pressure, atm
Rotational atherectomy, %
Transient vessel closure, %
Transient or persistent side branch closure, %
AHA/ACC  American Heart Association/American Colle
left main coronary artery; LCX  left circumflex artery; RC
igure 1. Incidence and magnitude of creatine kinase-myocardial band (
spirin-sensitive (open bars) patients after percutaneous coronary intervention.yonecrosis occurred more frequently in the aspirin-
esistant patients than in the aspirin-sensitive patients. The
ncidence of any CK-MB elevation was 51.7% versus 24.6%
n the aspirin-resistant and -sensitive groups, respectively (p
0.006) (Fig. 1). Elevation of TnI occurred in 65.5% of
spirin-resistant patients and 38.5% of aspirin-sensitive
atients (p  0.012) (Fig. 1). The median peak values of
K-MB and TnI in the aspirin-resistant and -sensitive
roups, respectively, were 20 and 17 U/l and 6.3 and 0.85
g/ml. The continuous relationship between ARU and
ics
in-Sensitive
 122)
Aspirin-Resistant
(n  29) p Value
0.223
36.8 47.7
38.7 18.2
22.1 29.5
2.5 4.5
6  0.57 2.51  0.55 0.121
12.3 11.4 1.000
2.5 0 1.000
27.9 44.8 0.117
0.543
20.9 25.0
79.1 75.0
91 100 0.124
9  92 371  98 0.918
.3  0.5 1.5  0.7 1.000
89.3 93.1 0.737
.4  0.8 1.6  0.8 0.240
.8  3.4 15.1  3.1 0.673
7.4 3.4 0.688
0 3.4 0.192
9.0 10.3 0.733
Cardiology; LAD  left anterior descending artery; LM 
ight coronary artery.
B) and troponin I (TnI) elevation in aspirin-resistant (solid bars) anderist
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March 17, 2004:1122–6 Aspirin Resistance and Myonecrosis After PCIK-MB, TnI, or bleeding index was not observed. No
n-hospital mortality or urgent target vessel revasculariza-
ion occurred among any of the patients. Variables associ-
ted with CK-MB elevation by univariate analysis were
spirin resistance (p  0.006), bifurcation lesion (p 
.035), B2/C lesion (p  0.029), and number of stents used
p  0.04). Multivariate analysis revealed aspirin resistance
odds ratio [OR] 2.9; 95% confidence interval [CI] 1.2 to
.9; p  0.015) and bifurcation lesion (OR 2.8; 95% CI 1.3
o 6.0; p  0.007) to be independent predictors of CK-MB
levation after PCI.
ISCUSSION
his is the first study to demonstrate that, despite adequate
retreatment with clopidogrel, patients undergoing non-
rgent PCI are at increased risk of myonecrosis when they
re determined to be aspirin-resistant using a point-of-care
ssay, compared with those who are aspirin-sensitive. Ele-
ation of CK-MB has been shown to be associated with a
igher incidence of death, myocardial infarction, and repeat
evascularization after PCI (16). Prevention of post-PCI
yonecrosis, therefore, is of clinical importance. Aspirin has
een shown to reduce acute thrombotic complications of
alloon angioplasty (17–19). Thienopyridine pretreatment
2–7) and the addition of intravenous glycoprotein IIb/IIIa
nhibitors (20–23) further improve the outcomes of patients
ndergoing elective or urgent PCI. However, the role of
spirin in PCI has not been defined in the contemporary era
sing double or triple antiplatelet therapy.
Aspirin resistance describes the clinical observation of the
nability of aspirin to prevent thrombotic complications or
he laboratory phenomenon of absence of the effect of
spirin on platelet inhibition tests. Four prior studies dem-
nstrated the association of adverse clinical events in pa-
ients with aspirin resistance as determined by different
ssays (8,12–14). Our study extends these observations and
rovides further evidence on the clinical significance of
spirin resistance. We collected the data prospectively in
table patients undergoing PCI while interventionalists and
aboratory personnel performing assays for myonecrosis
ere blinded to platelet inhibition results. The relatively
igh percentages of CK-MB and TnI elevations in our
opulation may be due to the high rates of diabetes (40%)
nd complex lesions (75% B2/C lesions), and diffuse
therosclerosis as reflected by small reference diameters of
2.6 mm. Despite receiving the maximal antiplatelet effect
f clopidogrel with a 300-mg loading dose given 12 h
efore non-urgent PCI, aspirin-resistant patients had a
.9-fold increased risk of CK-MB elevation compared with
spirin-sensitive patients.
Our study has several potential limitations. First, the
tudy population was small and Asian in origin. Important
rends may not be detected because of a lack of statistical
ignificance and it is not known whether ethnicity plays a
ole in the differences in aspirin resistance. Second, ourtudy did not have a prospective randomized design, and
here might be unrecognized confounders that may influ-
nce the occurrence of myonecrosis in addition to aspirin
esponsiveness. Third, the antiplatelet effect of aspirin may
uctuate in patients at the same dosage. A single baseline
easurement may not reflect the extent of platelet inhibi-
ion over long periods of time. However, during PCI when
aximal antithrombotic action is desirable, a point-of-care
latelet inhibition assay may give instant information on the
fficacy of aspirin, regardless of previous antiplatelet effect.
Finally, we conclude that aspirin resistance is associated
ith a 2.9-fold increased incidence of myonecrosis as
videnced by CK-MB elevation following non-urgent PCI
ith adequate clopidogrel pretreatment. Our results may
ave implications for the need of identification of aspirin
esistance in patients undergoing PCI and the use of
lternative or additional antithrombotic therapy to mini-
ize procedural complications.
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ivision of Cardiology, Department of Medicine, The University
f Hong Kong, Queen Mary Hospital, Hong Kong, China.
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